Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins

Table 1 Comparative table of clinical trials investigating the efficacy of therapies based on glitazones and gliptins versus placebo

Reference	N	Treatment	Baseline values for HbA_1c [%]	Results		Statistical significance
Reference	N	Treatment	Baseline values for HbA_1c [%]	Glycated hemoglobin HbA_1c [%]	Fasting plasma glucose (FPG) [mmol/L]	Statistical significance
Lü et al., 2011 [8]	236	SU + PLB	In the range of 7.0 to 12.0	−0.28 ± 0.11	+0.17 ± 1.92	SS
Lü et al., 2011 [8]	236	SU + PIO 30 mg	In the range of 7.0 to 12.0	−0.92 ± 0.10	−1.48 ± 2.08	p < 0.05
Scherbaum et al., 2002 [9]	84	PLB + diet				SS
	89	PIO 15 mg + diet		−0.92	−1.9
	78	PIO 30 mg + diet		−1.05	−2.0
Yang et al., 2012 [10]	395	MET + PLB	8.5			SS
Yang et al., 2012 [10]	395	MET + SIT	8.5	−0.9	−1.2	p < 0.001
Barzilai et al., 2011 [11]	206	PLB	7.8			SS
Barzilai et al., 2011 [11]	206	SIT 50 (100) mg	7.8	−0.7	−1.5	p < 0.001
Yang et al., 2015 [12]	136	SU + PLB	8.6	−0.2		SS
Yang et al., 2015 [12]	143	SU + VIL 100 mg	8.7	−0.7		p < 0.001
Lukashevich et al., 2014 [15]	160	PLB + MET + glimepiride	8.80	−0.25	+0.02	SS
Lukashevich et al., 2014 [15]	158	VIL + MET + glimepiride	8.75	−1.01	−1.11	p < 0.001

EQW exenatide, MET metformin, PIO pioglitazone, SIT sitagliptin, VIL vildagliptin, SU sulphonylurea, PLB placebo, SS statistically singnificant, SN statistically non-significant

ISSN: 1758-5996